Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report

BackgroundPancreatic cancer has a poor prognosis, and it is traditionally treated with chemotherapy. Fortunately, immunotherapy has rapidly changed the landscape of solid tumor treatment, and improving the survival of cancer patients. However, pancreatic cancer is non-immunogenic, and single agent i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yanghui Ye, Song Zheng
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	pancreatic cancer immunotherapy chemotherapy next generation sequencing (NGS) SMAD4 TSC2 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/15c0afc3c53940c79d946b14f310061e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:15c0afc3c53940c79d946b14f310061e
record_format	dspace
spelling	oai:doaj.org-article:15c0afc3c53940c79d946b14f310061e2021-11-22T06:38:27ZSuccessful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report1664-322410.3389/fimmu.2021.785400https://doaj.org/article/15c0afc3c53940c79d946b14f310061e2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.785400/fullhttps://doaj.org/toc/1664-3224BackgroundPancreatic cancer has a poor prognosis, and it is traditionally treated with chemotherapy. Fortunately, immunotherapy has rapidly changed the landscape of solid tumor treatment, and improving the survival of cancer patients. However, pancreatic cancer is non-immunogenic, and single agent immunotherapies are unfavorable to its prognosis.Case PresentationHere, we report a case of stage IV pancreatic cancer in a patient with TSC2 and SMAD4 mutations treated with immunotherapy when the disease progressed after multi-line chemotherapy. Next generation sequencing (NGS) confirmed the presence of TSC2 and SMAD4 mutations and microsatellite stability (MSS). When the disease progressed after chemotherapy, a combination strategy was devised consisting of chemotherapy (S-1) and sintilimab. The patient had a partial response to therapy with this regimen, the lesions were significantly reduced and nearly disappeared. In metastatic pancreatic cancer, responses of this magnitude are rarely seen.ConclusionsThis outcome reveals that this combination can be effective in treating metastatic pancreatic cancer, especially in pancreatic cancer patients with SMAD4 and TSC2 mutations. This may help increase the use of this therapy in large-scale clinical research.Yanghui YeYanghui YeSong ZhengSong ZhengSong ZhengFrontiers Media S.A.articlepancreatic cancerimmunotherapychemotherapynext generation sequencing (NGS)SMAD4TSC2Immunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pancreatic cancer immunotherapy chemotherapy next generation sequencing (NGS) SMAD4 TSC2 Immunologic diseases. Allergy RC581-607
spellingShingle	pancreatic cancer immunotherapy chemotherapy next generation sequencing (NGS) SMAD4 TSC2 Immunologic diseases. Allergy RC581-607 Yanghui Ye Yanghui Ye Song Zheng Song Zheng Song Zheng Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report
description	BackgroundPancreatic cancer has a poor prognosis, and it is traditionally treated with chemotherapy. Fortunately, immunotherapy has rapidly changed the landscape of solid tumor treatment, and improving the survival of cancer patients. However, pancreatic cancer is non-immunogenic, and single agent immunotherapies are unfavorable to its prognosis.Case PresentationHere, we report a case of stage IV pancreatic cancer in a patient with TSC2 and SMAD4 mutations treated with immunotherapy when the disease progressed after multi-line chemotherapy. Next generation sequencing (NGS) confirmed the presence of TSC2 and SMAD4 mutations and microsatellite stability (MSS). When the disease progressed after chemotherapy, a combination strategy was devised consisting of chemotherapy (S-1) and sintilimab. The patient had a partial response to therapy with this regimen, the lesions were significantly reduced and nearly disappeared. In metastatic pancreatic cancer, responses of this magnitude are rarely seen.ConclusionsThis outcome reveals that this combination can be effective in treating metastatic pancreatic cancer, especially in pancreatic cancer patients with SMAD4 and TSC2 mutations. This may help increase the use of this therapy in large-scale clinical research.
format	article
author	Yanghui Ye Yanghui Ye Song Zheng Song Zheng Song Zheng
author_facet	Yanghui Ye Yanghui Ye Song Zheng Song Zheng Song Zheng
author_sort	Yanghui Ye
title	Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report
title_short	Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report
title_full	Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report
title_fullStr	Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report
title_full_unstemmed	Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report
title_sort	successful immunotherapy for pancreatic cancer in a patient with tsc2 and smad4 mutations: a case report
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/15c0afc3c53940c79d946b14f310061e
work_keys_str_mv	AT yanghuiye successfulimmunotherapyforpancreaticcancerinapatientwithtsc2andsmad4mutationsacasereport AT yanghuiye successfulimmunotherapyforpancreaticcancerinapatientwithtsc2andsmad4mutationsacasereport AT songzheng successfulimmunotherapyforpancreaticcancerinapatientwithtsc2andsmad4mutationsacasereport AT songzheng successfulimmunotherapyforpancreaticcancerinapatientwithtsc2andsmad4mutationsacasereport AT songzheng successfulimmunotherapyforpancreaticcancerinapatientwithtsc2andsmad4mutationsacasereport
_version_	1718418086525140992

Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report

Ejemplares similares